Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of COMP360 in PTSD
NCT05312151Phase 2Completed
- Sponsor
- COMPASS Pathways
- Start
- Jun 2022
- Primary completion
- Feb 2024
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
A Phase 2 trial of psilocybin in post-traumatic stress disorder (PTSD), sponsored by COMPASS Pathways. Started Jun 2022; status: completed.
02
Drugs
psilocybin
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT05312151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05312151.